Search

Displaying results 1671 - 1680 of 8517 in total
  1. Drug

    Phosphoric acid

    go.drugbank.com/drugs/DB09394
    ApprovedInvestigational

    Phosphoric Acid is a colorless, odorless phosphorus-containing inorganic acid. Phosphoric acid is a sequestering agent which binds many divalent cations, including Fe++, Cu++, Ca++, and Mg++.

  2. Drug

    Voxelotor

    go.drugbank.com/drugs/DB14975
    Approved

    [L10403] It was developed by Global Blood Therapeutics, Inc. … [T734] Voxelotor was granted accelerated FDA approval on November 25 2019, as it is likely to be a promising treatment for the 100,000 individuals in the U.S. suffering from the disease, in addition

  3. Drug

    Sibutramine

    go.drugbank.com/drugs/DB01105
    ApprovedIllicitWithdrawn

    It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the United States. … Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity.

  4. Drug

    Hexestrol

    go.drugbank.com/drugs/DB07931
    ApprovedWithdrawn

    A synthetic estrogen that has been used as a hormonal antineoplastic agent.

  5. Drug

    Pimecrolimus

    go.drugbank.com/drugs/DB00337
    ApprovedInvestigational

    It is currently available as a topic cream used in the treatment of atopic dermatitis (eczema). … Pimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007.

  6. Drug

    Pioglitazone

    go.drugbank.com/drugs/DB01132
    ApprovedInvestigational

    Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus. … [L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in vivo_ with little consequence

  7. Drug

    Oxilofrine

    go.drugbank.com/drugs/DB11610
    Approved

    Oxilofrine is used in combination with [DB11609] as an antitussive. It is currently marketed in Canada by Valeant under the tradename Cophylac.

  8. Drug

    Ormeloxifene

    go.drugbank.com/drugs/DB13310
    Experimental

    In India, ormeloxifene has been marketed since the 1990s as a non-hormonal, non-steroidal oral contraceptive taken once a week,[A251450] and it was later introduced for the treatment of dysfunctional uterine … [A251475] The use of levormeloxifene for the treatment of reduced bone turnover and the prevention of atherosclerosis has been evaluated; however, drug development was discontinued due to adverse events

  9. Drug

    Tridihexethyl

    go.drugbank.com/drugs/DB00505
    ApprovedWithdrawn

    Tridihexethyl is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract.

  10. Drug

    Caplacizumab

    go.drugbank.com/drugs/DB06081
    ApprovedInvestigational

    Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression